Last reviewed · How we verify
Ranocaine (PROPOXYCAINE HYDROCHLORIDE)
Propoxycaine Hydrochloride (Ranocaine) is a marketed local anesthetic that blocks sodium channels to prevent pain signal transmission, competing in a crowded market with several same-target drugs including articaine, bepridil, brompheniramine, butacaine, and chlorphenamine. A key strength of Ranocaine is its patent protection until 2028, providing a period of exclusivity that could help maintain market share against off-patent competitors. The primary risk is the strong competition from other patented and generic same-target drugs, particularly articaine, which has a patent extending to 2039.
At a glance
| Generic name | PROPOXYCAINE HYDROCHLORIDE |
|---|---|
| Drug class | propoxycaine |
| Target | Sodium channel alpha subunits; brain (Types I, II, III) |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ranocaine CI brief — competitive landscape report
- Ranocaine updates RSS · CI watch RSS